Phase I and II clinical trials in 2017–2019 investigated lorlatinib efficacy in ROS1- and ALK-rearranged NSCLC patients via addressing objective response rate (ORR) and median progression-free survival (PFS) [92, 93]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.